Cardiovascular Disease and Uric Acid Cardiovascular Disease and Uric Acid
Does lowering of uric acid in gout lead to cardiovascular and renal benefits? A new study investigates the pathogenic impact of uric acid levels on CVD and CKD risk, but much is still unclear.European Heart Journal
The U.S. Food and Drug Administration (FDA) is warning that preliminary results from a safety clinical trial show an increased risk of heart-related death with febuxostat (Uloric) compared to another gout medicine called allopurinol. We required the Uloric drug manufacturer, Takeda Pharmaceuticals, to conduct this safety study when we approved the medicine in 2009. Once we receive the final results from the manufacturer, we will conduct a comprehensive review and will update the public with any new information.
ConclusionEATP lowered the serum uric acid level and increased the urine uric acid level through excretion, which is useful in the treatment of gout. Hence the EATP was found to be helpful in the treatment of gout.
Case Report: A male in his 40s with tophaceous gout presented to the rheumatology clinic for follow-up. Four months earlier the patient ’s allopurinol dose had been increased from 200mg BID to 400mg BID as the patient was unable to achieve a uric acid of
NEW YORK (Reuters Health)—The recombinant shingles vaccine (RZV) is associated with an increased risk of gout flare, and a new study suggests other vaccines may trigger flares as well, researchers say. “Our findings are novel because for the first time, we have identified a trigger for gout flares that presumably acts through [an inflammatory] pathway,... [Read More]
The recombinant shingles vaccine (RZV) is associated with an increased risk of gout flare, and a new study suggests other vaccines may trigger flares as well, researchers say.Reuters Health Information
Conditions: Hyperuricemia; Gout Interventions: Drug: ABP-671; Other: Placebo Sponsor: Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd. Recruiting
Abstract The present review is aimed at providing a comprehensive summary of the botanical characteristics, ethnomedicinal uses, phytochemical, pharmacological, and toxicological studies of the genus Ajuga L. The extensive literature survey revealed Ajuga L. species to be a group of important medicinal plants used for the ethnomedical treatment of rheumatism, fever, gout, sclerosis, analgesia, inflammation, hypertension, hyperglycemia, joint pain, palsy, amenorrhea, etc., although only a few reports address the clinical use and toxicity of these plants. Currently, more than 280 chemical constituents have been isol...
ConclusionsLesinurad plus allopurinol therapy compared with febuxostat seems an effective option for the management of hyperuricemia in patients who did not reach serum urate target to previous allopurinol monotherapy, associated to cost-savings for the Spanish Health System.Key Points•Lesinurad, in combination with allopurinol, has been recently authorized as second-line treatment of hyperuricemia in gout patients.•Lesinurad plus allopurinol provided higher effectiveness in terms of quality-adjusted-life-years (14.79) than febuxostat (14.69).•Lesinurad plus allopurinol resulted less costly (total cost/per p...
Objectives A previous study suggested that colchicine may cause leukopenia, and increase the risk of infection, such as pneumonia. Thus, we investigated the potential relationship between colchicine use and risk of developing pneumonia. Methods Data were collected from Taiwan’s National Health Insurance Research Database, a nationwide, population-based database. A 13-year retrospective cohort study was conducted, and all investigated subjects were identified by International Classification of Disease, Ninth Revision, Clinical Modification, codes between 2000 and 2012. Propensity score matching was applied to adjus...
Abstract OBJECTIVE: To assess factors associated with the ability to achieve and maintain target serum urate (SU) with allopurinol in patients with gout. METHODS: We used National VA national databases from 2002-2012. Eligible patients had ≥1 inpatient or ≥2 outpatient visits with a diagnostic code for gout, filled a new index allopurinol prescription, had at least one post-treatment SU measured, and met 12-month observability rule. Treatment successes were defined as the achievement of post-index SU